IP Library Granted Patent US 9,687,549
Granted Patent B2
US 9,687,549 · App. 15/056,853 · Granted Jun 27, 2017

Topical pharmaceutical gel composition of diclofenac sodium

Inventor: Bala Chandran Nayar (Somerset, NJ)
Assignee: Lupin Atlantis Holdings SA
A61K47/02A61K9/0014A61K31/196A61K47/10A61K47/14A61K47/183A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,687,549
App. No.
15/056,853
Granted
Jun 27, 2017
Kind
B2
Abstract

A topical pharmaceutical gel compositions of diclofenac sodium, is provided. The topical gel composition contains at least about 10% w/w diclofenac sodium and is suitable for twice daily application.

Claims (54)

1. A topical pharmaceutical gel composition suitable for twice daily application of diclofenac comprising:

at least about 10% w/w of diclofenac sodium;

about 5-25% w/w of a glycol solvent;

about 1-6% w/w of at least one gelling agent;

about 0.01-0.75% w/w of at least one preservative;

about 0.01-1% w/w of at least one antioxidant;

about 1-10% w/w of salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

2. The gel composition of claim 1 , wherein the glycol solvent is selected from the group consisting of propylene glycol, polyethylene glycol, ethylene glycol, butylene glycol, and hexalylene glycol, and mixtures thereof.

3. The gel composition of claim 2 , wherein the glycol solvent is propylene glycol.

4. The gel composition of claim 1 , wherein the gelling agent is selected from the group consisting of carbomers, xanthan gum, acacia, tragacanth, sodium alginate, gelatin, modified starches, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methyl cellulose, co-polymers formed between maleic anhydride and methyl vinyl ether, methacrylate derivatives, polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, polyvinyl alcohol and mixtures thereof.

5. The gel composition of claim 4 , wherein the gelling agent is carbomer.

6. The gel composition of claim 1 , wherein the at least one preservative is selected from the group consisting of methyl paraben, propyl paraben, chlorocresol, thomersal, sorbic acid, potassium sorbate and mixtures thereof.

7. The gel composition of claim 1 , wherein the antioxidant is selected from the group consisting of edetate disodium, sodium sulphite, sodium metabisulfite, propyl gallate, edetate trisodium, tocopherol derivatives, butylated hydroxyl toluene, butylated hydroxyl anisole, ascorbic acid, fumaric acid, malic acid, and citric acid, and mixtures thereor.

8. The gel composition of claim 1 , wherein the antioxidant is edentate disodium.

9. The gel composition of claim 1 , wherein the salicylic acid ester is selected from the group consisting of methyl salicylate, ethyl salicylate and glycol monosalicylate, and mixtures thereof.

10. The gel composition of claim 1 , wherein the acidic and basic agents are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, acetic acid, lactic acid and citric acid, and mixtures thereof.

11. The gel composition of claim 1 , wherein the gel is devoid of either C 2 to C 4 alkanol, monoalkyl ether of diethylene glycol, or fatty alcohol.

12. The gel composition of claim 1 , wherein twice daily application of said gel composition provides steady state blood levels of diclofenac that are comparable to steady state blood levels of diclofenac achieved with 4 times daily application of diclofenac sodium 1% or 3% topical gel.

13. A method for the treatment of painful conditions, inflammations and/or rheumatic diseases comprising topically applying the gel composition of claim 1 to a patient in need thereof.

14. A topical pharmaceutical gel composition suitable for twice daily application of diclofenac or salts consisting of:

about 10-15% w/w of diclofenac sodium as the sole active ingredient;

about 5-25% w/w of propylene glycol;

about 1-6% w/w of carbomer;

about 0.01-0.75% w/w of methyl paraben and propyl paraben;

about 0.01-1% w/w of at least one edetate disodium;

about 1-10% w/w of methyl salicylate;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

15. The topical pharmaceutical gel composition of claim 14 , wherein the composition consists of:

about 10% w/w of diclofenac sodium as the sole active ingredient;

about 10% w/w of propylene glycol;

about 3.5% w/w of carbomer;

about 0.4% w/w of methyl paraben and propyl paraben;

about 0.17% w/w of at least one edetate disodium;

about 3% w/w of methyl salicylate;

about 0.2% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

16. The topical pharmaceutical gel composition of claim 14 , wherein the composition consists of:

about 14% w/w of diclofenac sodium as the sole active ingredient,

about 20% w/w of propylene glycol,

about 2.5% w/w of carbomer,

about 0.4% w/w of methyl paraben and propyl paraben,

about 0.17% w/w of at least one edetate disodium,

about 7% w/w of methyl salicylate,

about 0.3% w/w of menthol

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

17. A method for the treatment of painful conditions, inflammations and/or rheumatic diseases comprising topically applying twice per day a gel composition to a skin surface of a patient in need thereof, wherein the gel composition consists essentially of diclofenac sodium as the sole active ingredient and the diclofenac sodium is present at a concentration of about 10% w/w to about 15% w/w.

18. The method of claim 17 , wherein the diclofenac sodium is present at a concentration of about 10% w/w.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: LUPIN ATLANTIS HOLDINGS SA
To: LUPIN INC.
Reel/Frame 045855/0640 →
Continuity (2)
Provisional Application 62133333 · Mar 14, 2015
Related Publication 20160263029A1 · Sep 15, 2016